Source: Annual Congress 2002 - Cellular reactions in allergy in humans and animals
Disease area: Airway diseases

Abstract

Bacground: The intensified CD30 expression is associated with the apoptosis pathway of human Th-2 type cells. The CD30 mediated apoptosis is thought to be inhibited by Bcl-2.
Aim: The sCD30 (plasma) and Bcl-2 (lymphocytes lysates, ex vivo) concentrations were estimated and compared with unspecific serum apoptosis marker – anti-Annexin V antibodies.
Methods: 21 atopic subjects (AT, 12 men and 9 women, mean age-28,1) with seasonal allergic rhinitis and episodic asthma symptoms, sensitive to grass pollens, were included into the trial. Control group (C) consisted of 15 healthy donors. The enzyme immunoassay (CD30 DAKO, Bcl-2 ELISA and anti-Annexin V Bender MedSystem) for soluble CD30 (plasma), Bcl-2 (lysates of isolated lymphocytes, ex vivo) and anti-Annexin V antibodies (serum) were used.
Results: The Bcl-2 and anti-Annexin V antibodies concentrations were comparable in atopic and control groups (Bcl-2 mean ±] SEM: AT - 348 ±] 21 pg/mL vs C - 317 ±] 33 pg/mL, anti-Annexin V mean ±] SEM: AT - 2,4 ±] 1,34 U/mL vs C - 1,6 ±] 0,39 U/mL, p>0,05 test U Mann-Whitney). The sCD30 concentration was significantly increased in atopic patients (sCD30 mean ±] SEM: AT - 31,74 ±] 7,3 U/mL vs C - 10,9 ±] 1,4 U/mL; p<0,05 test U Mann-Whitney). Moderate correlation between CD30 and anti-Annexin antibodies was observed (r = -0,48, p<0,05; Spearman test).
Conclusion: Apoptosis of Th-2 type lymphocytes seems to be suppressed in a different than Bcl-2-regulated pathway in atopic patients.

Rating:

Share or cite this content

Citations should be made in the following way:
S. Zeglen, B. Rogala (Zabrze, Poland). sCD30, Bcl-2 and anti-annexin V antibodies - apoptosis associated soluble molecules in atopic subjects. Eur Respir J 2002; 20: Suppl. 38, 304

Member's Comments

No comment yet.

Related content which might interest you: The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma Source: Eur Respir J 2001; 18: 45-52 Year: 2001 MEMP1972A, an anti-M1 prime monoclonal antibody, reduces serum IgE in healthy and allergic rhinitis subjects Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012 Detection of serum anti-endothelial cell antibodies (AECA) in COPD rats Source: Annual Congress 2011 - Cell biology of lung disease Year: 2011 CD14 promoter polymorphism C159T is associated with soluble CD14 but not serum IgE levels in a large population of German children Source: Eur Respir J 2003; 22: Suppl. 45, 579s Year: 2003 CD95 expression, annexin-V binding of phosphatidylserine and caspase-3 activity in lymphocytes in bronchial asthma Source: Annual Congress 2008 - Risk factors for allergic asthma and allergic rhinitis Year: 2008 The death receptor CD95 (Fas, Apo-1) expression and Annexin-V binding of phosphatidylserine in lymphocytes in bronchial asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 757s Year: 2006 Soluble intercellular adhesion molecule 1 (ICAM-1) antigen in sera of asthmatic children Source: Eur Respir J 2002; 20: Suppl. 38, 140s Year: 2002 Activity of pro- and anti- apoptotic factors mRNA expression in eosinophils of asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 321s Year: 2004 High prevalence of serum IgA antibodies against gliadin in patients with interstitial lung diseases confirmed by immunoblotting Source: Eur Respir J 2003; 22: Suppl. 45, 227s Year: 2003 Interaction of T-cell and antigen presenting cell co-stimulatory genes in childhood IgE Source: Eur Respir J 2010; 35: 54-63 Year: 2010 Up regulation of CD23 (FceRII) expression in human airway smooth muscle cells after exposure to IL-13 Source: Annual Congress 2005 - Regulation of the allergic and asthmatic response Year: 2005 Circulating CD50+, CD54+ cells in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 770s Year: 2007 TNF-alpha, T-lymphocytes: CD4, CD25, and lymphocytes expressing adhesion molecules: CD11b, CD18, in inflammatory processes of the lower respiratory tract Source: Eur Respir J 2002; 20: Suppl. 38, 274s Year: 2002 CD23 (receptor of IgE) in response to trauma Source: Eur Respir J 2007; 30: Suppl. 51, 267s Year: 2007 Study of immunological parameters (IgG, IgM, IgE, IgA, C3, C4, CRP, and phagocytic function (ST-NBT, SP-NBT), in female traditional bakers compared with asthmatics and normal control groups Source: Eur Respir J 2001; 18: Suppl. 33, 282s Year: 2001 Efficacy of an anti-IL13 monoclonal antibody, lebrikizumab, in adults with inadequately controlled asthma is enhanced in those with high periostin levels Source: Annual Congress 2011 - New treatments for airway disease Year: 2011 Activation of human lung mast cells by monomeric immunoglobulin E Source: Eur Respir J 2005; 25: 858-863 Year: 2005 Omalizumab, an anti-immunoglobin E antibody, is not associated with an increased risk of immunological reactions Source: Eur Respir J 2002; 20: Suppl. 38, 108s Year: 2002 The type II and clara cell specific monoclonal antibody (MMC4) recognises aminopeptidase N Source: Eur Respir J 2004; 24: Suppl. 48, 719s Year: 2004 IgG Fcγ receptor expression on BAL neutrophils, pneumonia, and HIV-infection Source: Eur Respir J 2003; 22: Suppl. 45, 333s Year: 2003